Logo

Vertex's Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Receives the US FDA's Approval in Children Aged 6 to 11 with Certain Mutations in Cystic Fibrosis

Share this

Vertex's Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Receives the US FDA's Approval in Children Aged 6 to 11 with Certain Mutations in Cystic Fibrosis

Shots:

  • The approval is based on a P-III study evaluating the safety- PK & efficacy of Trikafta in 66 children aged 6-11yrs. old with CF with either two copies of F508del mutations or one copy of F508del mutation & one minimal function mutation for 24wks.
  • The company has filed the application in EMA & MHRA and plans to file for expanded use in Switzerland- Australia & Israel in 2021. Additionally- a new dosage strength of Trikafta is now available (elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 75 mg and ivacaftor 75 mg)
  • Trikafta is an approved therapy for patients aged ≥12yrs. with CF with certain mutations in the US- Switzerland- Australia- Israel- EU & UK as Kaftrio + Kalydeco

  | Ref: Vertex | Image: vertex

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions